June 27, 2025 01:07 PM EDTUpdated 01:31 PM
R&D
FDA+

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

Lei Lei Wu

News Reporter

The FDA is elim­i­nat­ing a safe­ty mon­i­tor­ing pro­gram for all CAR-T ther­a­pies, say­ing the cell ther­a­pies can be used safe­ly and ef­fec­tive­ly with­out it. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J dealt blow in fight over its 340B re­bate mod­el

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

A din­ner in Paris re­vived talks for Sanofi's $9.5B deal for Blue­print

In­novent brings a new mech­a­nism to obe­si­ty mar­ket with Chi­na ap­proval

Bill Meury brings new per­spec­tive to In­cyte as Hop­penot re­tires; Ex-Mor­phoSys CEO leads re­vi­tal­ized Vor Bio

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times